Benzinga | Feb 12, 2021 09:04AM EST

Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $170

Piper Sandler analyst Christopher Raymond maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $165 to $170.